掉秤20斤，竟有5～8斤是肌肉？难怪很多人看着瘦了，身体却越来越虚。2026年9月，全球首款“增肌针”阿皮特古单抗（Apitegromab）在美获批。比罕见病更出圈的，是它能让掉秤时的肌肉流失“直接减半”！可市场打开了，天价却逃不开，“一年31万美元”的保肌费，你觉得值吗？
文献：
[1] MCPHERRON A C, LAWLER A M, LEE S J. Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member[J]. Nature, 1997, 387(6628): 83-90. DOI: 10.1038/387083a0.
[2] CRAWFORD T O, SERVAIS L, MERCURI E, et al. A plain language summary of the SAPPHIRE clinical trial of apitegromab in children and young adults with spinal muscular atrophy[J]. Expert Review of Neurotherapeutics, 2026, 26(1): 101-120. DOI: 10.1080/14737175.2025.2579903.
[3] PRATLEY R E, DENHAM D S, TRIVEDI R, et al. Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial[J]. Nature Medicine, 2026, 32(7): 2673-2678. DOI: 10.1038/s41591-026-04440-4.
[4] SATIJA B. Muscle-preserving drugs could generate over $30 billion in sales by 2035,
TD Cowen says[N/OL]. (2025-06-20)
[5] SCHOLAR ROCK HOLDING CORPORATION. Scholar Rock 44th Annual J.P. Morgan Healthcare Conference slides[EB/OL]. (2026-01-12)
[6] CRAWFORD T O, SERVAIS L, MERCURI E, et al. Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial[J]. The Lancet Neurology, 2025, 24(9): 727-739. DOI: 10.1016/S1474-4422(25)00225-X.
[7] U.S. FOOD AND DRUG ADMINISTRATION. FDA approves first therapy to target muscle loss in spinal muscular atrophy[EB/OL]. (2026-09-11)
